A novel intraperitoneal therapy for gastric cancer with DFP-10825, a unique RNAi therapeutic targeting thymidylate synthase, in a peritoneally disseminated xenograft model.

Hidenori AndoMasakazu FukushimaKiyoshi EshimaTaichi HasuiTaro ShimizuYu IshimaCheng-Long HuangHiromi WadaTatsuhiro Ishida

Published in: Cancer medicine (2019)

Intraperitoneal injection of DFP-10825 demonstrated effective antitumor activity without systemic severe adverse effects via the selective delivery of RNAi molecules into disseminated tumors in the peritoneal cavity. Our current study indicates that DFP-10825 could become an alternative option to improve the outcomes of patients with peritoneally disseminated gastric cancer.

Keyphrases

cancer therapy
ultrasound guided
metabolic syndrome
drug induced
drug delivery
adipose tissue
weight loss